Oligodendroglioma

Current Treatment Options in Oncology

Volumn 4, Issue 6, 2003, Pages 479-490

  Ellis, Thomas L ^a   Stieber, Volker W ^b   Austin, Rebekah C ^b  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

Clin Oncol; Oligodendrogliomas; Pilocytic Astrocytoma; Radiat Oncol Biol Phys; Temozolomide

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; DEXAMETHASONE; LOMUSTINE; PCV PROTOCOL; PROCARBAZINE; VINCRISTINE;

ADJUVANT CHEMOTHERAPY; CRANIOTOMY; EMERGENCY HEALTH SERVICE; GENETICS; HUMAN; LIFESTYLE; MULTIMODALITY CANCER THERAPY; OLIGODENDROGLIOMA; RADIATION DOSE FRACTIONATION; REVIEW;

ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; CRANIOTOMY; DEXAMETHASONE; DOSE FRACTIONATION; EMERGENCY MEDICAL SERVICES; HUMANS; LIFE STYLE; LOMUSTINE; OLIGODENDROGLIOMA; PROCARBAZINE; VINCRISTINE;

EID: 2342616883     PISSN: 15272729     EISSN: 15346277     Source Type: Journal    
DOI: 10.1007/s11864-003-0048-1     Document Type: Article

References (62)

1. Mork SJ, Lindegaard KF, Halvorsen TB, et al.: Oligoden-droglioma: incidence and biological behavior in a defined population. J Neurosurg 1985, 63:881–889.
2. Peterson K, Cairncross JG: Oligodendroglioma. Cancer Invest 1996, 14:243–251.
3. Shaw EG, Scheithauer BW, O’Fallon JR, et al.: Oligoden-drogliomas: the Mayo Clinic experience. J Neurosurg 1992, 76:428–434.
4. Shaw EG, Scheithauer BW, O’Fallon JR, Davis DH: Mixed oligoastrocytomas: a survival and prognostic factor analysis. Neurosurgery 1994, 34:577–582. DOI: 10.1097/00006123-199404000-00002
5. Mork SJ, Halvorsen TB, Lindegaard KF, Eide GE: Oligo-dendroglioma: histologic evaluation and prognosis. J Neuropathol Exp Neurol 1986, 45:65–78. DOI: 10.1097/00005072-198601000-00006
6. Leonardi MA, Lumenta CB: Oligodendrogliomas in the CT/MR-era. Acta Neurochir (Wien) 2001, 143:1195–1203. DOI: 10.1007/s007010100014
7. Perry JR: Oligodendrogliomas: clinical and genetic correlations. Curr Opin Neurol 2001, 14:705–710. DOI: 10.1097/00019052-200112000-00005
8. Peterson K, Paleologos N, Forsyth P, et al.: Salvage chemotherapy for oligodendroglioma. J Neurosurg 1996, 85:597–601. DOI: 10.3171/jns.1996.85.4.0597
9. Fortin D, Cairncross GJ, Hammond RR: Oligodendro-glioma: an appraisal of recent data pertaining to diagnosis and treatment. Neurosurgery 1999, 45:1279–1291. DOI: 10.1097/00006123-199912000-00001
10. Fortin D, MacDonald DR, Stitt L, Cairncross JG: PCV for oligodendroglial tumors: in search of prognostic factors for response and survival. Can J Neurol Sci 2001, 28:215–223.
11. Bauman GS, Ino Y, Ueki K, et al.: Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas. Int J Radiat Oncol Biol Phys 2000, 48:825–830. DOI: 10.1016/S0360-3016(00)00703-3
12. Dong SM, Pang JC, Poon WS, et al.: Concurrent hypermethylation of multiple genes is associated with grade of oligodendroglial tumors. J Neuropathol Exp Neurol 2001, 60:808–816.
13. Nigro JM, Takahashi MA, Ginzinger DG, et al.: Detection of 1p and 19q loss in oligodendroglioma by quantitative microsatellite analysis, a real-time quantitative polymerase chain reaction assay. Am J Pathol 2001, 158:1253–1262.
14. Zlatescu MC, TehraniYazdi A, Sasaki H, et al.: Tumor location and growth pattern correlate with genetic signature in oligodendroglial neoplasms. Cancer Res 2001, 61:6713–6715.
15. Soffietti R, Ruda R, Bradac GB, Schiffer D: PCV chemotherapy for recurrent oligodendrogliomas and oli-goastrocytomas. Neurosurgery 1998, 43:1066–1073. DOI: 10.1097/00006123-199811000-00035
16. Cairncross JG, MacDonald DR: Successful chemotherapy for recurrent malignant oligodendroglioma. Ann Neurol 1988, 23:360–364. An important paper documenting successful results with PCV chemotherapy. DOI: 10.1002/ana.410230408
17. Cairncross JG, MacDonald DR, Ramsay DA: Aggressive oligodendroglioma: a chemosensitive tumor. Neurosurgery 1992, 31:78–82. DOI: 10.1097/00006123-199207000-00011
18. Glass J, Hochberg FH, Gruber ML, et al.: The treatment of oligodendrogliomas and mixed oligoden-droglioma- astrocytomas with PCV chemotherapy. J Neurosurg 1992, 76:741–745.
19. Levin VA, Edwards MS, Wright DC, et al.: Modified procarbazine, CCNU, and vincristine (PCV 3) combination chemotherapy in the treatment of malignant brain tumors. Cancer Treat Rep 1980, 64:237–244.
20. Hofer S, Herrmann R: Chemotherapy for malignant brain tumors of astrocytic and oligodendroglial lineage. J Cancer Res Clin Oncol 2001, 127:91–95. DOI: 10.1007/s004320000171
21. Bauman GS, Cairncross JG: Multidisciplinary management of adult anaplastic oligodendrogliomas and anaplastic mixed oligo-astrocytomas. Semin Radiat Oncol 200111,:170–180.
22. Cairncross JG, Ueki K, Zlatescu MC, et al.: Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998, 90:1473–1479. DOI: 10.1093/jnci/90.19.1473
23. Brown J, Byers T, Thompson K, et al.: Nutrition during and after cancer treatment: a guide for informed choices by cancer survivors. CA Cancer J Clin 2001, 51:153–187.
24. Brownson RC, Reif JS, Chang JC, Davis JR: An analysis of occupational risks for brain cancer. Am J Public Health 1990, 80:169–172.
25. Ricci PE, Dungan DH: Imaging of low- and intermediate-grade gliomas. Semin Radiat Oncol 2001, 11:103–112.This paper includes pertinent diagnostic imaging criteria. DOI: 10.1053/srao.2001.21420
26. Leiguarda R, Sierra J, Pardal C, Zambrano D: Effect of large doses of methylprednisolone on supratentorial intracranial tumors: a clinical and CAT scan evaluation. Eur Neurol 1985, 24:23–32.
27. Yamada K, Ushio Y, Hayakawa T, et al.: Effects of methylprednisolone on peritumoral brain edema: a quan-titative autoradiographic study. J Neurosurg 1983, 59:612–619.
28. Tatter SB: Neurosurgical management of low- and intermediate-grade gliomas. Semin Radiat Oncol 2001, 11:113–123. DOI: 10.1053/srao.2001.21430
29. Tatter SB: Neurosurgical management of brain tumors. Neuroimaging Clin N Am 1999, 9:779–799. A comprehensive overview of surgical management of brain tumors.
30. Del Maestro RF, Megyesi JF, Farrell CL: Mechanisms of tumor-associated edema: a review. Can J Neurol Sci 1990, 17:177–183.
31. Grossman SA, Suleman S, Eller S: Novel COX-2 inhibitor is equal to dexamethasone in prolonging survival in rats with 9L gliomass. Proc Am Soc Clin Oncol 2001, 20:53a.
32. Laws ER Jr: The conservative management of primary gliomas of the brain. Clin Neurosurg 1990, 36:367–374.
33. Wallner KE, Gonzales M, Sheline GE: Treatment of oli-godendrogliomas with or without postoperative irra-diation. J Neurosurg 1988, 68:684–688.
34. Karim AB, Afra D, Cornu P, et al.: Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European Organization for Research and Treatment of Cancer study 22845 with the Medical Research Council study BRO4: an interim analysis. Int J Radiat Oncol Biol Phys 2002, 52:316–324. DOI: 10.1016/S0360-3016(01)02692-X
35. Lote K, Egeland T, Hager B, et al.: Survival, prognostic factors, and therapeutic efficacy in low-grade glioma: a retrospective study in 379 patients. J Clin Oncol 1997, 15:3129–3140.
36. Lindegaard KF, Mork SJ, Eide GE, et al.: Statistical analysis of clinicopathological features, radiotherapy, and survival in 170 cases of oligodendroglioma. J Neurosurg 1987, 67:224–230.
37. Karim AB, Maat B, Hatlevoll R, et al.: A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) study 22844. Int J Radiat Oncol Biol Phys 1996, 36:549–556. A phase III trial analyzing the optimal radiotherapy dose. DOI: 10.1016/S0360-3016(96)00352-5
38. Shaw E, Arusell R, Scheithauer B, et al.: Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. J Clin Oncol 2002, 20:2267–2276. A phase III trial that analyzes the optimal dose of radiation. DOI: 10.1200/JCO.2002.09.126
39. North CA, North RB, Epstein JA, et al.: Low-grade cerebral astrocytomas: survival and quality of life after radiation therapy. Cancer 1990, 66:6–14. DOI: 10.1002/1097-0142(19900701)66:1<6::AID-CNCR2820660103>3.0.CO;2-F
40. Marks JE, Wong J: The risk of cerebral radionecrosis in relation to dose, time, and fractionation: a follow-up study. Prog Exp Tumor Res 1985, 29:210–218.
41. Hammack J, Shaw E, Ivnik R: Neurocognitive function in patients receiving radiation therapy for supratentorial low-grade gliomas: a North Central Cancer Treatment Group prospective study (abstract). Proc Am Soc Clin Oncol 1995, 14:151. This paper analyzes a subgroup of patients from a phase II randomized prospective trial for evidence of cognitive deficits resulting from treatment.
42. Brown PD, Buckner JC, Brown CA, Brown CA: The effects of radiation on cognitive function in patients with low-grade glioma. Proc Am Soc Clin Oncol 2001, 20:58a. This paper analyzes a subgroup of patients from a phase II randomized prospective trial for evidence of cognitive deficits resulting from treatment.
43. Eyre HJ, Crowley JJ, Townsend JJ, et al.: A randomized trial of radiotherapy versus radiotherapy plus CCNU for incompletely resected low-grade gliomas: a Southwest Oncology Group study. J Neurosurg 1993, 78:909–914. A phase III trial demonstrating inefficacy of single-agent chemotherapy. DOI: 10.3171/jns.1993.78.6.0909
44. van den Bent MJ, Kros JM, Heimans JJ, et al.: Response rate and prognostic factors of recurrent oligodendro-glioma treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group. Neurology 1998, 51:1140–1145.
45. Buckner JC, Smith JS, Nelson DF: Phase II trial of pro-carbazine, CCNU, and vincristine (PCV) as initial therapy in patients with low-grade oligodendro-glioma or oligoastrocytoma: efficacy results and associations with chromosome 1p and 19q loss [abstract]. Proc Am Soc Clin Oncol 1999, 18:140.
46. Thoron L, Colinskas C, McDevitt K: Adjuvant I-PCV chemotherapy for treatment of low-grade oligoden-droglioma. Proc Am Soc Clin Oncol 1997, 16:410.
47. Stewart LA: Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 2002, 359:1011–1018. DOI: 10.1016/S0140-6736(02)08091-1
48. Boiardi A, Silvani A, Pozzi A, et al.: Advantage of treating anaplastic gliomas with aggressive protocol combining chemotherapy and radiotherapy. J Neurooncol 1997, 34:179–185. DOI: 10.1023/A:1005705624858
49. Bouffet E, Jouvet A, Thiesse P, Sindou M: Chemotherapy for aggressive or anaplastic high-grade oligodendro-gliomas and oligoastrocytomas: better than a salvage treatment. Br J Neurosurg 1998, 12:217–222. DOI: 10.1080/02688699845023
50. Cairncross G, MacDonald D, Ludwin S, et al.: Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1994, 12:2013–2021. A landmark paper demonstrating the high efficacy of multiagent chemotherapy in treating high-grade oligodendroglioma.
51. Chinot OL, Honore S, Dufour H, et al.: Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. J Clin Oncol 2001, 19:2449–2455.
52. Levin VA, Yung WK, Bruner J, et al.: Phase II study of accelerated fractionation radiation therapy with carboplatin followed by PCV chemotherapy for the treatment of anaplastic gliomas. Int J Radiat Oncol Biol Phys 2002, 53:58–66. DOI: 10.1016/S0360-3016(01)02819-X
53. Shaw E, Scott C, Souhami L, et al.: Single-dose radio-surgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05. Int J Radiat Oncol Biol Phys 2000, 47:291–298. A landmark radiosurgery dose-escalation trial. DOI: 10.1016/S0360-3016(99)00507-6
54. van Rijn J, Heimans JJ, van den BJ, et al.: Survival of human glioma cells treated with various combinations of temozolomide and X-rays. Int J Radiat Oncol Biol Phys 2000, 47:779–784. DOI: 10.1016/S0360-3016(99)00539-8
55. van den Bent, Chinot O, Boogerd W, et al.: EORTC study 26972: second line temozolomide chemotherapy in recurrent oligodendroglial tumors after PCV chemotherapy. Proc Am Soc Clin Oncol 2001, 20:52a.
56. Friedman AH, Cokgor I, Edwards S, Edwards AE: Phase II treatment of anaplastic oligodendroglioma and low-grade gliomas with temozolomide [abstract]. Proc Am Soc Clin Oncol 2000, 19:169.
57. Viviers L, Brada M, Hines F, Hines F: A phase II trial of primary chemotherapy with temozolomide in patients with low-grade cerebral gliomas [abstract]. Proc Am Soc Clin Oncol 2000, 19:167.
58. van den Bent MJ, Keime-Guibert F, Brandes AA, et al.: Temozolomide chemotherapy in recurrent oligoden-droglioma. Neurology 2001, 57:340–342.
59. Smith JS, Alderete B, Minn Y, et al.: Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological sub-type. Oncogene 1999, 18:4144–4152. DOI: 10.1038/sj.onc.1202759
60. Reifenberger J, Reifenberger G, Liu L, et al.: Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol 1994, 145:1175–1190.
61. Smith JS, Perry A, Borell TJ, et al.: Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oli-goastrocytomas. J Clin Oncol 2000, 18:636–645.
62. Bigner SH, Matthews MR, Rasheed BK, et al.: Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization. Am J Pathol 1999, 155:375–386.